DIVISION OF

CORPORATION FINANCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

Mail Stop 4546

May 10, 2017

Daniel P. Gold President and Chief Executive Officer MEI Pharma, Inc. 11975 El Camino Real, Suite 101 San Diego, CA 92130

Re: MEI Pharma, Inc.

Registration Statement on Form S-3

Filed May 4, 2017 File No. 333-217645

Dear Mr. Gold:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Christine Westbrook at (202) 551-5019 with any questions.

Sincerely,

/s/ Mary Beth Breslin for

Suzanne Hayes Assistant Director Office of Healthcare and Insurance

cc: Steven A. Navarro, Esq.
Morgan, Lewis & Bockius LLP